Expression systems for alpha6-containing nicotinic acetylcholine receptors and methods of use thereof

By co-expressing and genetically modifying heterologous nucleic acids encoding α6, β2, β3 subunits and chaperone proteins in recombinant cells, functional nAChR is solved, and the problem of difficulty in expressing nAChR containing α6 in the prior art is achieved, and drug discovery is achieved Efficient screening and regulation of therapeutic targets for affective disorders.

CN119072489APending Publication Date: 2024-12-03JANSSEN PHARMA NV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033274.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-11
Filing Date
2023-02-10
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art has difficulty in robustly expressing α6-containing nicotine acetylcholine receptor (nAChR) in recombinant systems, resulting in hindering drug discovery.

Method used

Isolated recombinant cells are provided, including α6 subunit, β2 subunit, β3 subunit encoding nAChR, and heterologous nucleic acids of chaperone proteins BARP, SULT2B1, LAMP5, CHAT and NACHO, and form functional α6β2β3nAChR through co-expression and genetic modification. or α6/3β2β3nAChR, used to identify agonists, antagonists, or positive allosteric regulators.

Benefits of technology

The efficient expression of nAChR containing α6 is achieved, providing a reliable cellular system for drug discovery, able to identify and screen effective drug molecules, and enhance the regulatory capacity of the therapeutic targets of affective disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072489A_ABST
    Figure CN119072489A_ABST
Patent Text Reader

Abstract

Disclosed herein are isolated recombinant cells for expressing an alpha 6-containing nicotinic acetylcholine receptor (nAChR) and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 309,092, filed on February 11, 2022, which is incorporated herein by reference in its entirety. Technical Field

[0003] The present invention relates to isolated recombinant cells for expressing α6-containing nicotinic acetylcholine receptors (nAChRs) and methods of using the same.

[0004] Reference sequence listing submitted electronically

[0005] This application contains a sequence listing that has been submitted electronically in ST.26 format and is hereby incorporated by reference in its entirety. The ST.26 copy created on January 26, 2023 is named JAB7137WOPCT1_SL.XML and is 16,108 bytes in size. Background Art

[0006] Major depressive disorder is characterized by debilitating symptoms, including hopelessness and anhedonia. There is strong evidence linking the dopamine system from the ventral tegmental area to the nucleus accumbens (mesolimbic dopamine system) to reward-related, hedonic, and motivated behaviors. Currently, therapeutic interventions that specifically target dopamine neurons are not available.

[0007] Acetylcholine (ACh) plays a major role in the regulation of dopamine neurons. ACh binds to two major receptors: ionotropic nicotinic (nAChR) acetylcholine receptors and metabotropic muscarinic (mAChR) acetylcholine receptors. nAChR is a non-selective cation channel that depolarizes dopamine neurons and causes calcium to flow into cells. This depolarization results in the generation of action potentials at high frequencies, known as burst release (>20Hz). It is this burst release of dopamine neurons that encodes the physiological effects of the mesolimbic dopamine system in the above-mentioned behaviors. Therefore, regulating nAChR can produce therapeutic interventions for affective disorders.

[0008] nAChR is a membrane-bound complex assembled from five subunits, each of which consists of a large extracellular N-terminal domain (NTD), a transmembrane domain (TMD) consisting of four transmembrane α-helices (TM1-TM4) connected by intracellular loops and extracellular loops (including a large second intracellular loop (ICL)), and an extracellular short C-terminus. Therefore, the pentameric nAChR complex contains three structural entities: an extracellular domain containing an orthosteric site, a transmembrane domain containing an ion channel, and an intracellular domain, which are assembled from the NTD, TMD, and an ICL with five subunits, respectively.

[0009] nAChRs containing the nAChR subunit α6 (CHRNA6, Accession No.: NM_004198) are selectively expressed in dopamine neurons and provide a therapeutic target for modulating the mesolimbic dopamine system to treat affective disorders. However, drug discovery efforts have been hampered by the inability to express α6-containing nAChRs in recombinant systems commonly used for such screening.

[0010] There remains a need to develop recombinant cells that robustly express α6-containing nAChRs and can be used for drug discovery. Summary of the invention

[0011] Provided herein are isolated recombinant cells comprising: a) a heterologous nucleic acid encoding the α6 subunit of nAChR; b) a heterologous nucleic acid encoding BARP; c) a heterologous nucleic acid encoding SULT2B1; d) a heterologous nucleic acid encoding LAMP5; e) a heterologous nucleic acid encoding CHAT; and f) a heterologous nucleic acid encoding NACHO.

[0012] In one embodiment of the isolated recombinant cell, it further comprises: g) a heterologous nucleic acid encoding the β2 subunit of nAChR; and h) a heterologous nucleic acid encoding the β3 subunit of nAChR, wherein the α6 subunit, β2 subunit and β3 subunit of nAChR form an α6β2β3 nAChR.

[0013] In another embodiment of the isolated recombinant cell, the α6 subunit of the nAChR is an α6 / 3 chimera, wherein all or part of the sequence of the second intracellular loop (ICL) of the α6 subunit is replaced by the corresponding sequence of the second ICL of the α3 subunit of the nAChR, and wherein the α6 / 3 chimera of the nAChR forms a chimeric α6 / 3β2β3nAChR with the β2 subunit and the β3 subunit.

[0014] In yet another embodiment of the isolated recombinant cell, the recombinant cell is a mammalian cell.

[0015] In yet another embodiment of the isolated recombinant cell, the mammalian cell is selected from the group consisting of human embryonic kidney 293T (HEK293T) cells, HEK293F cells, HeLa cells, Chinese hamster ovary (CHO) cells, NIH 3T3 cells, MCF-7 cells, Hep G2 cells, baby hamster kidney (BHK) cells, and Cos7 cells.

[0016] In yet another embodiment of the isolated recombinant cell, the α6 subunit of nAChR comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.

[0017] In yet another embodiment of the isolated recombinant cell, the β2 subunit of nAChR comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:6.

[0018] In yet another embodiment of the isolated recombinant cell, the β3 subunit of nAChR comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:7.

[0019] In yet another embodiment of the isolated recombinant cell, the second ICL of the α6 subunit comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:2, and the second ICL of the α3 subunit comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:4.

[0020] In yet another embodiment of the isolated recombinant cell, the α6 / 3 chimera comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:5.

[0021] In yet another embodiment of the isolated recombinant cell, the BARP comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:8.

[0022] In yet another embodiment of the isolated recombinant cell, SULT2B1 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:9.

[0023] In yet another embodiment of the isolated recombinant cell, LAMP5 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:10.

[0024] In yet another embodiment of the isolated recombinant cell, the CHAT comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:11.

[0025] In yet another embodiment of the isolated recombinant cell, the NACHO comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:12.

[0026] Also provided herein is a method for identifying an agonist, antagonist or positive allosteric modulator of an α6-containing nAChR, the method comprising: a) contacting an isolated recombinant cell as provided above with an agent; and b) determining the activity of the α6-containing nAChR of the isolated recombinant cell, wherein if the agent enhances the activity of the α6-containing nAChR, compared to the activity of the α6-containing nAChR when the isolated recombinant cell is not contacted with the agent, the agent is identified as an agonist or positive allosteric modulator (PAM), and if the agent decreases the activity of the α6-containing nAChR, the agent is identified as an antagonist.

[0027] Also provided herein is a method for identifying an agonist, antagonist or positive allosteric modulator of α6β2β3nAChR, the method comprising: a) contacting an isolated recombinant cell as provided above with an agent; and b) determining the activity of the α6β2β3nAChR of the isolated recombinant cell, wherein if the agent enhances the activity of the α6β2β3nAChR, compared to the activity of the α6β2β3nAChR when the isolated recombinant cell is not contacted with the agent, the agent is identified as an agonist or positive allosteric modulator (PAM), and if the agent decreases the activity of the α6β2β3nAChR, the agent is identified as an antagonist.

[0028] In one embodiment of the above method, step b) comprises measuring calcium flux of the isolated recombinant cell, wherein the agent is identified as an agonist if the agent enhances calcium flux compared to calcium flux when the isolated recombinant cell is not contacted with the agent.

[0029] In another embodiment of the above method, step b) comprises measuring calcium flux and nicotine-induced calcium flux of the isolated recombinant cell, wherein the agent is identified as a PAM if the agent does not enhance calcium flux and enhances nicotine-induced calcium flux as compared to the calcium flux and nicotine-induced calcium flux of the isolated recombinant cell when the cell is not contacted with the agent.

[0030] In yet another embodiment of the above method, step b) comprises measuring nicotine-induced calcium flux of the isolated recombinant cell, wherein the agent is identified as an antagonist if the agent reduces nicotine-induced calcium flux as compared to nicotine-induced calcium flux when the isolated recombinant cell is not contacted with the agent.

[0031] In yet another embodiment of the methods provided above, the isolated recombinant cells are incubated at about 25°C-35°C for about 20 hours-50 hours prior to contacting with the agent.

[0032] In yet another embodiment of the methods provided above, the pharmaceutical agent is a small molecule or a peptide.

[0033] Also provided herein is a kit comprising (i) an isolated recombinant cell as provided above and (ii) instructions for use. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1A is a graph showing the functional expression of α6β2β3 nAChR when co-expressed with different combinations of chaperone proteins (BARP+SULT2B1+LAMP5+NACHO or BARP+SULT2B1+LAMP5+NACHO+CHAT) and incubated at 30°C before testing.

[0035] Figure 1B is a graph showing the functional expression of α6 / 3β2β3 nAChR when co-expressed with different combinations of chaperone proteins (BARP+SULT2B1+LAMP5+NACHO or BARP+SULT2B1+LAMP5+NACHO+CHAT) and incubated at 37°C before testing.

[0036] Figure 1C is a graph showing the functional expression of α6 / 3β2β3 nAChR when co-expressed with different combinations of chaperone proteins (BARP+SULT2B1+LAMP5+NACHO or BARP+SULT2B1+LAMP5+NACHO+CHAT) and incubated at 30°C before testing.

[0037] Figure 2A It is a graph of FLIPR signals of recombinant cells expressing α6 / 3β2β3 after the first incubation with different concentrations of DHbE (a known antagonist of α6-containing nAChR) and the second incubation with nicotine.

[0038] Figure 2B It is a graph of FLIPR signals of recombinant cells expressing α6 / 3β2β3 after the first incubation with different concentrations of MLA (a known antagonist of α6-containing nAChR) and the second incubation with nicotine.

[0039] Figure 2C It is a graph of FLIPR signals of recombinant cells expressing α6 / 3β2β3 after a first incubation with different concentrations of mecamylamine (a known antagonist of α6-containing nAChR) and a second incubation with nicotine.

[0040] Figure 2D It is a graph of FLIPR signals of recombinant cells expressing α6 / 3β2β3 after a first incubation with different concentrations of α-conotoxin MII (a known antagonist of α6-containing nAChR) and a second incubation with nicotine. DETAILED DESCRIPTION

[0041] Various publications, articles, and patents are cited or described in the background and throughout the specification; each of these references is incorporated herein by reference in its entirety. The discussion of documents, acts, materials, devices, articles, etc. included in this specification is intended to provide a context for the present invention. Such discussion is not an admission that any or all of these matters form part of the prior art with respect to any invention disclosed or claimed.

[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Otherwise, certain terms used herein have the meanings described in this specification.

[0043] It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0044] Unless otherwise indicated, any numerical value, such as a concentration or concentration range described herein, is understood to be modified by the term "about" in all cases. Therefore, numerical values ​​generally include ± 10% of the value. For example, a concentration of 1 mg / ml includes 0.9 mg / ml to 1.1 mg / ml. Similarly, a concentration range of 1% to 10% (w / v) includes 0.9% (w / v) to 11% (w / v). Unless the context clearly indicates otherwise, as used herein, the numerical range used explicitly includes all possible subranges, all single values ​​within the range, including integers within such ranges and fractions within the range.

[0045] Unless otherwise indicated, the term "at least" preceding a series of elements should be understood to refer to each element in the series. Those skilled in the art will recognize, or will be able to ascertain using only routine experimentation, a variety of equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the present invention.

[0046] As used herein, the terms "comprises," "including," "having," or "containing," or any other variation thereof, should be understood to mean including the specified integer or group of integers but not excluding any other integer or group of integers, and are intended to be non-exclusive or open-ended. For example, a composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements, but may include other elements not expressly listed or inherent to these compositions, mixtures, processes, methods, articles, or apparatuses. In addition, unless expressly indicated to the contrary, "or" refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any of the following: A is true (or present) and B is false (or absent), A is false (or absent) and B is true (or present), and both A and B are true (or present).

[0047] As used herein, the connection term "and / or" between multiple listed elements is understood to include both single options and combined options. For example, where two elements are connected by "and / or", the first option refers to the application of the first element without the second element. The second option refers to the application of the second element without the first element. The third option refers to the application of the first element and the second element together. Any of these options is understood to fall within the meaning and therefore meets the requirements of the term "and / or" as used herein. The parallel applicability of more than one option is also understood to fall within the meaning and therefore meets the requirements of the term "and / or".

[0048] As used herein, the term "consisting of" used throughout the specification and claims means including any listed integer or group of integers, but additional integers or groups of integers cannot be added to the specified method, structure, or composition.

[0049] As used herein, the term "consisting essentially of" used throughout the specification and claims means including any recited integer or group of integers, and optionally including any recited integer or group of integers that does not materially change the basic or novel characteristics of the specified method, structure, or composition. See MPEP §2 111.03.

[0050] It should also be understood that when referring to dimensions or characteristics of components of the preferred invention, the use of "about," "approximately," "substantially," and similar terms herein indicates that the described dimensions / characteristics are not strict boundaries or parameters and do not exclude minor variations that are functionally the same or similar, as understood by those of ordinary skill in the art. At a minimum, such references including numerical parameters will include variations using mathematical and industrial principles accepted in the art (e.g., rounding, measurement or other systematic errors, manufacturing tolerances, etc.) without changing the least significant digits.

[0051] In the context of two or more nucleic acids or polypeptide sequences, the term "identical" or "identity" percentage refers to two or more sequences or subsequences that are identical or have a specified percentage of identical amino acid residues or nucleotides when compared and aligned to obtain maximum correspondence, as measured using a sequence comparison algorithm in the following sequence comparison algorithms or by visual inspection. For sequence alignment, a sequence is usually used as a reference sequence to which a test sequence is compared. When using a sequence alignment algorithm, the test sequence and the reference sequence are input into a computer, subsequence coordinates are specified (if necessary), and the program parameters of the sequence algorithm are specified. Then, the sequence comparison algorithm calculates the sequence identity percentage for the test sequence relative to the reference sequence based on the specified program parameters.

[0052] Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by using the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol., 48:443 (1970), by searching the similarity method of Pearson & Lipman (Proc. Natl. Acad. Sci. USA 85:2444 (1988)), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally, Current Protocols in Molecular Biology, FM Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1995 Supplement) (Ausubel)).

[0053] Examples of algorithms suitable for determining percentages of sequence identity and sequence similarity are BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1990) J. Mol. Biol., 215: 403-410 and Altschul et al., (1997) Nucleic Acids Res. 25: 3389-3402, respectively. Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information. The algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that match or satisfy some positive threshold score T when aligned with words of the same length in the database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits serve as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence as far as the cumulative alignment score can be increased.

[0054] For nucleotide sequences, cumulative scores are calculated using the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatched residues; always < 0). For amino acid sequences, a scoring matrix is ​​used to calculate the cumulative score. Extension of the word hits in each direction stops when: the cumulative alignment score drops by the amount X from its maximum achieved value; the cumulative score becomes zero or lower due to the accumulation of one or more negative score residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a word length (W) of 11, an expectation (E) of 10, M = 5, N = -4, and a comparison of both chains by default. For amino acid sequences, the BLASTP program uses a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix by default (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89: 10915 (1992)).

[0055] In addition to calculating the percentage of sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proc. Natl. g Acad. Sci. USA 90:5873-5787 (1993)). One similarity measure provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of a test nucleic acid to a reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0056] Another indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid immunologically cross-reacts with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions.

[0057] As used herein, the term "polynucleotide", which is synonymously referred to as "nucleic acid molecule", "nucleotide" or "nucleic acid", refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotide" includes, but is not limited to, single-stranded and double-stranded DNA, DNA that is a mixture of single-stranded and double-stranded regions, single-stranded and double-stranded RNA, and RNA that is a mixture of single-stranded and double-stranded regions, and hybrid molecules containing DNA and RNA that may be single-stranded or more typically double-stranded or a mixture of single-stranded and double-stranded regions. In addition, "polynucleotide" refers to a triple-stranded region comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNA or RNA containing one or more modified bases, and DNA or RNA having a main chain modified for stability or other reasons. "Modified" bases include, for example, tritylated bases and rare bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" includes chemically, enzymatically, or metabolically modified forms of polynucleotides that commonly occur in nature, as well as chemical forms of DNA and RNA that are unique to viruses and cells."Polynucleotide" also includes relatively short nucleic acid chains, commonly referred to as oligonucleotides.

[0058] As used herein, the terms "peptide", "polypeptide" or "protein" may refer to molecules composed of amino acids and may be recognized as proteins by those skilled in the art. Conventional single-letter or three-letter codes for amino acid residues are used herein. The terms "peptide", "polypeptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interspersed with non-amino acids. The term also encompasses amino acid polymers that have been modified naturally or by intervention; natural or interventional modifications are, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. The definition also includes, for example, polypeptides containing one or more amino acid analogs (including, for example, non-natural amino acids, etc.) and other modifications known in the art.

[0059] The peptide sequences described herein are written according to the usual convention, with the N-terminal region of the peptide on the left and the C-terminal region on the right. Although isomeric forms of amino acids are known, unless otherwise expressly indicated, it is the L form of the amino acid represented.

[0060] Isolated recombinant cells and methods for preparing recombinant cells

[0061] The invention disclosed herein is based at least in part on the unexpected discovery that co-expression of certain chaperone proteins with α6-containing nicotinic acetylcholine receptors (nAChRs) (such as α6β2β3nAChRs) in cells produces cells that highly express α6-containing nAChRs, making the cells useful for drug discovery. Provided herein are methods for preparing recombinant cells expressing the α6 subunit of nAChR and isolated recombinant cells for expressing the α6 subunit of nAChR. In some embodiments, the second ICL of the α6 subunit may be partially or completely replaced by the corresponding amino acid sequence of the second ICL of the α3 subunit of nAChR, which may be referred to as an α6 / 3 chimeric protein. Also provided herein are methods for preparing recombinant cells expressing α6β2β3nAChR and isolated recombinant cells for expressing α6β2β3nAChR. In some embodiments, the α6 subunit may be an α6 / 3 chimeric protein as described above, and the recombinant cell expresses α6 / 3β2β3nAChR.

[0062] As used herein, the terms "α6β2β3 nicotinic acetylcholine receptor", "α6β2β3 nAChR", "α6β2β3 nicotinic acetylcholine receptor" and "alpha6beta2beta3 nAChR" are used interchangeably and refer to the α6β2β3 nicotinic acetylcholine receptor protein, preferably human α6β2β3 nAChR, which is a member of the cholinergic receptor protein family.

[0063] α6β2β3nAChR is a ligand-gated ion channel composed of α6, β2 and β3 subunits. The α6 subunit is encoded by the gene CHRNA6 (NM_004198), the β2 subunit is encoded by the gene CHRNB2 (NM_000748) and the β3 subunit is encoded by the gene CHRNB3 (NM_000749). When expressed together, these subunits co-assemble to form α6β2β3nAChR.

[0064] According to the present invention, the term α6β2β3nAChR also encompasses chimeric α6 / 3β2β3nAChRs, in which the second ICL of the α6 subunit is partially or completely replaced by the corresponding amino acid sequence of the second ICL of the α3 subunit of the nAChR. In one embodiment, a portion of the second ICL of the α6 subunit is replaced by the amino acid sequence of the second ICL of the α3 subunit of the nAChR. The α3 subunit is encoded by the gene CHRNA3 (NM_000743).

[0065] "Recombinant cell" refers to one or more single cells and a recombinant cell line in which the cell heterologously expresses a protein. As used herein, "heterologous expression" of a protein in a cell refers to modifying the cell to express the protein by introducing an exogenous nucleic acid (e.g., an exogenous nucleic acid encoding a protein to be expressed) into the cell. "Heterologous nucleic acid" refers to a cell exogenous nucleic acid introduced into the cell. In some embodiments, the heterologous nucleic acid is DNA. In some embodiments, the heterologous nucleic acid is RNA. Various methods can be used to achieve heterologous expression of a protein in a cell. For example, an expression vector comprising a nucleic acid encoding a protein can be introduced into a cell, and the nucleic acid can be operably linked to a nucleic acid encoding a promoter (e.g., a constitutive promoter) that can drive protein expression.

[0066] As used herein, the term "expression" refers to the biosynthesis of a gene product. The term encompasses the transcription of a gene into RNA. The term also encompasses the translation of RNA into one or more polypeptides, and also encompasses all naturally occurring post-transcriptional and post-translational modifications.

[0067] In general, the present invention relates to a method for preparing or generating cells expressing α6-containing nAChRs (such as α6β2β3nAChRs, including chimeric α6 / 3β2β3nAChRs as described above) that can be used for drug discovery. In one embodiment, the method includes introducing the following items into the cell: nucleic acids encoding α6 subunits of nAChRs (including chimeric α6 / 3 subunits), nucleic acids encoding β-anchoring and regulatory proteins (BARP; Accession No.: NM_152769), nucleic acids encoding sulfotransferase family 2B member 1 (SULT2B1; Accession No.: NM_177973), nucleic acids encoding lysosomal associated membrane protein 5 (LAMP5; Accession No.: NM_012261), nucleic acids encoding choline O-acetyltransferase (CHAT; Accession No.: NM_020984), and nucleic acids encoding transmembrane protein 35 (TMEM35; also known as NACHO; Accession No.: NM_021637). The nucleic acids encoding the α6 subunits of nAChR (including chimeric α6 / 3 subunits) and chaperones (i.e., BARP, SULT2B1, LAMP5, CHAT, and NACHO) can be in expression vectors (e.g., in a single expression vector or in separate expression vectors). In some embodiments, the nucleic acids encoding the α6 subunits of nAChR (including chimeric α6 / 3 subunits) and chaperones (i.e., BARP, SULT2B1, LAMP5, CHAT, and NACHO) are operably linked to a promoter capable of driving expression of the corresponding protein. In some embodiments, the promoter is a constitutive promoter.

[0068] In another aspect, the method comprises introducing into a cell a nucleic acid encoding the α6 subunit of an α6β2β3 nAChR (including a chimeric α6 / 3 subunit as described above), a nucleic acid encoding the β2 subunit of an α6β2β3 nAChR, a nucleic acid encoding the β3 subunit of an α6β2β3 nAChR, a nucleic acid encoding a BARP, a nucleic acid encoding SULT2B1, a nucleic acid encoding LAMP5, a nucleic acid encoding CHAT, and a nucleic acid encoding NACHO, wherein the cell produced by the method expresses the α6β2β3 nAChR (including a chimeric α6 / 3 nAChR as described above) at an increased level compared to the same cell without the nucleic acids encoding BARP, SULT2B1, LAMP5, CHAT, and NACHO.

[0069] In another aspect, the present invention relates to cells genetically modified to express the α6 (including the chimeric α6 / 3 as described above) subunit, β2 subunit and β3 subunit of nAChR; BARP; SULT2B1; LAMP5; CHAT and NACHO, wherein the genetically modified cells express these proteins at increased levels relative to the expression of the same proteins in unmodified cells under the same (or substantially the same) conditions.

[0070] In another aspect, the present invention relates to an isolated recombinant cell comprising at least one expression vector selected from the group consisting of: an expression vector comprising a nucleic acid sequence encoding BARP, an expression vector comprising a nucleic acid sequence encoding SULT2B1, an expression vector comprising a nucleic acid sequence encoding LAMP5, an expression vector comprising a nucleic acid sequence encoding CHAT, and an expression vector comprising a nucleic acid sequence encoding NACHO.

[0071] In another aspect, the present invention relates to an isolated recombinant cell comprising a heterologous nucleic acid encoding an α6 subunit of a nAChR (including a chimeric α6 / 3 subunit of a nAChR as described above), a heterologous nucleic acid encoding a β2 subunit of a nAChR, a heterologous nucleic acid encoding a β3 subunit of a nAChR, a heterologous nucleic acid encoding a BARP, a heterologous nucleic acid encoding a SULT2B1, a heterologous nucleic acid encoding a LAMP5, a heterologous nucleic acid encoding a CHAT, and a heterologous nucleic acid encoding a NACHO, wherein the α6 (including α6 / 3) subunit, the β2 subunit, and the β3 subunit form an α6β2β3 nAChR (or a chimeric α6 / 3β2β3 nAChR). In one embodiment, the heterologous nucleic acid is introduced into the recombinant cell in the form of an expression vector. In one embodiment, the isolated recombinant cells disclosed herein comprise an expression vector containing a nucleic acid encoding the α6 subunit of nAChR (including a nucleic acid encoding the α6 / 3 subunit as described above), an expression vector containing a nucleic acid encoding the β2 subunit of nAChR, an expression vector containing a nucleic acid encoding the β3 subunit of nAChR, an expression vector containing a nucleic acid encoding BARP, an expression vector containing a nucleic acid encoding SULT2B1, an expression vector containing a nucleic acid encoding LAMP5, an expression vector containing a nucleic acid encoding CHAT, and an expression vector containing a nucleic acid encoding NACHO.

[0072] In any of the embodiments described herein, nucleic acids encoding any one or more of the α6 (including α6 / 3), β2 and β3 subunits of nAChR; BARP; SULT2B1; LAMP5; CHAT and NACHO may be in a single expression vector or in separate expression vectors.

[0073] In one embodiment, the α6 subunit of nAChR comprises an amino acid sequence that is at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:1 (NM_004198.2 / NP_004189).

[0074]

[0075] In one embodiment, the second ICL of the α6 subunit comprises an amino acid sequence that is at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:2.

[0076]

[0077] In one embodiment, the α3 subunit of nAChR comprises an amino acid sequence that is at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:3 (NM_000743.5 / NP_000734.2).

[0078]

[0079] In one embodiment, the second ICL of the α3 subunit comprises an amino acid sequence that is at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:4.

[0080]

[0081] In one embodiment, an exemplary chimeric α6 / 3 comprises an amino acid sequence that is at least 855%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:5.

[0082]

[0083] In one embodiment, the β2 subunit of nAChR comprises an amino acid sequence that is at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:6 (NM_000748.3 / NP_000739.1).

[0084]

[0085] In one embodiment, the β3 subunit of nAChR comprises an amino acid sequence that is at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:7 (NM_000749.5 / NP_000740.1).

[0086]

[0087] In one embodiment, the BARP comprises an amino acid sequence having at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence of SEQ ID NO: 8 (XM_017026555.1 / XP_016882044.1). Alternatively, the BARP comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence of SEQ ID NO: 8, and has protein chaperone properties, including the property of enhancing the expression of the α6 subunit of nAChR (including the chimeric α6 / 3 subunit as described above).

[0088]

[0089]

[0090] In one embodiment, SULT2B1 comprises an amino acid sequence that is at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 9 (NM_177973.2 / NP_814444.1). Alternatively, SULT2B1 comprises an amino acid sequence that is at least 60%, at least 70%, at least 80%, at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 9, and has protein chaperone properties, including properties that enhance the expression of the α6 subunit of nAChR (including the chimeric α6 / 3 subunit as described above).

[0091]

[0092] In one embodiment, LAMP5 comprises an amino acid sequence having at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence of SEQ ID NO: 10 (NM_012261.4 / NP_036393.1). Alternatively, LAMP5 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identity to the amino acid sequence of SEQ ID NO: 10, and has protein chaperone properties, including properties that enhance the expression of the α6 subunit of nAChR (including the chimeric α6 / 3 subunit as described above).

[0093]

[0094] In one embodiment, the CHAT comprises an amino acid sequence that is at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11 (NM_020984.4 / NP_066264.4). Alternatively, the CHAT comprises an amino acid sequence that is at least 60%, at least 70%, at least 80%, at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 11, and has protein chaperone properties, including properties that enhance the expression of the α6 subunit of the nAChR (including the chimeric α6 / 3 subunit as described above).

[0095]

[0096] In one embodiment, NACHO comprises an amino acid sequence that is at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 12 (NM_021637.3 / NP_067650.1). Alternatively, NACHO comprises an amino acid sequence that is at least 60%, at least 70%, at least 80%, at least 85%, or at least 90%, or at least 95%, such as 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 12, and has protein chaperone properties, including properties that enhance the expression of the α6 subunit of nAChR (including the chimeric α6 / 3 subunit as described above).

[0097]

[0098] Any suitable means for introducing heterologous nucleic acid into cells can be used herein to prepare recombinant cells disclosed herein, such as DNA transfection (e.g., via DNA vectors) and RNA transduction. In one embodiment, heterologous nucleic acid to be introduced into cells to produce recombinant cells is prepared by using a vector, preferably an expression vector. The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which another DNA fragment can be inserted. Another type of vector is a viral vector, into which another DNA fragment can be inserted. An expression vector is one that can direct the expression of a gene operably connected thereto. The expression vector used herein comprises a nucleic acid encoding a protein sequence in a form suitable for expressing nucleic acid in a host cell. Therefore, an expression vector may include one or more regulatory sequences, such as a promoter operably connected to a nucleic acid sequence to be expressed, selected based on a host cell to be used for expression. When used with respect to an expression vector, "operably connected" is intended to indicate that the nucleotide sequence of interest is connected to a regulatory sequence in a manner that allows the expression of the nucleotide sequence (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into a host cell). It will be appreciated by those of ordinary skill in the art that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed and the level of expression of the protein desired, as well as the intended use of the vector.

[0099] According to the disclosure, any vector known to those skilled in the art can be used, such as plasmid, cosmid, phage vector or viral vector. In one embodiment, the vector is an expression vector, such as a plasmid. The vector may include any element of the conventional function of establishing the expression vector, such as a promoter, a ribosome binding element, a terminator, an enhancer, a selection marker and an origin of replication. The promoter may be a constitutive, inducible or repressible promoter. A variety of expression vectors capable of delivering nucleic acids to cells are known in the art and can be used herein. Conventional cloning techniques or artificial gene synthesis can be used to generate expression vectors according to embodiments of the present invention.

[0100] In view of the present disclosure, any cell known to those skilled in the art can be used to recombinantly express the α6 (including chimeric α6 / 3) subunit, β2 subunit, β3 subunit of nAChR; BARP; SULT2B1; LAMP5; CHAT and NACHO. In one embodiment, the recombinant cell is a mammalian cell. Suitable mammalian cells can be selected from human embryonic kidney 293T (HEK293T) cells, HEK293F cells, HeLa cells, Chinese hamster ovary (CHO) cells, NIH 3T3 cells, MCF-7 cells, Hep G2 cells, baby hamster kidney (BHK) cells and Cos7 cells.

[0101] Methods for identifying agonists, antagonists or positive allosteric modulators of α6β2β3 nAChR

[0102] Also provided herein are methods for identifying agonists, antagonists or positive allosteric modulators (PAMs) of α6-containing nAChRs (such as α6β2β3nAChRs, including chimeric α6 / 3β2β3nAChRs as described above). PAMs are compounds that bind at sites other than the active site on the surface of a protein and thus alter the conformation of the protein binding site.

[0103] In one embodiment, the method includes culturing the isolated recombinant cells disclosed herein under conditions of recombinant cell growth, contacting the recombinant cells with an agent, and determining whether the agent is an agonist, antagonist, or PAM of α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above), wherein the agonist or PAM enhances the activity of α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above) and the antagonist reduces the activity of α6β2β3nAChR compared to the activity of α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above) in recombinant cells not contacted with the agent. As used herein, an agonist refers to a molecule / compound / peptide used to enhance the function of α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above). As used herein, PAM refers to a molecule / compound / peptide that enhances the response effect of α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above) to a ligand without directly activating the receptor. As used herein, when used with respect to the activity of α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above), the term "enhancement", "enhanced", "increase" or "increased" refers to an increase in the signal through the receptor relative to the corresponding signal observed in cells to which an agonist or PAM is not applied. As used herein, an antagonist refers to a molecule / compound / peptide that is used to block, reduce or weaken the function of α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above). In a specific embodiment, the agent is a small molecule or a peptide.

[0104] In one embodiment, the FLIPR assay is used to identify agonists of calcium flux mediated by α6β2β3 nAChR (including chimeric α6 / 3β2β3 nAChR as described above). In this assay, recombinant cells are incubated with a calcium sensitive dye (such as Ca5), exposed to a test compound, and the agonists are detected by FLIPR. TETRA Imaging calcium flux.

[0105] In one embodiment, the FLIPR assay is used to identify antagonists of nicotine-induced α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above) mediated calcium flux. In this assay, recombinant cells are incubated with a calcium sensitive dye (such as Ca5). Using a double addition protocol, the recombinant cells are exposed to a test compound during a first duration and to nicotine (e.g., EC5) during a second duration. 80 (236 nM)). Then, by FLIPR TETRA Imaging calcium flux.

[0106] In one embodiment, the FLIPR assay is used to identify compounds that positively modulate or enhance nicotine-induced α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above) mediated calcium flux. In this assay, recombinant cells are incubated with a calcium sensitive dye (such as Ca5). Using a double addition protocol, recombinant cells are exposed to a test compound during a first duration and to nicotine (e.g., EC5) during a second duration. 80 (236 nM)). Then, by FLIPR TETRA Calcium flux is imaged. If a test compound enhances nicotine-induced α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above)-mediated calcium flux, but does not enhance calcium flux as an agonist (as determined above), then the test compound is referred to as a positive allosteric modulator (PAM) or enhancer of α6β2β3nAChR (including chimeric α6 / 3β2β3nAChR as described above).

[0107] In a preferred embodiment, the cells are incubated at about 25°C-35°C for about 20 hours to 50 hours prior to the FLIPR assay or other assay for measuring the activity of α6β2β3 nAChR (including chimeric α6 / 3β2β3 nAChR as described above). In some embodiments, the cells are incubated at about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31°C, about 32°C, about 33°C, about 34°C or about 35°C for about 20 hours, about 25 hours, about 30 hours, about 35 hours, about 40 hours, about 45 hours or about 50 hours prior to the assay.

[0108] Expression Systems and Kits

[0109] Also provided herein are expression systems and kits comprising isolated recombinant cells. The expression systems and kits may also include instructions for use.

[0110] Example

[0111] It will be appreciated by those skilled in the art that modifications may be made to the above embodiments without departing from the broad inventive concept of the present invention. Therefore, it should be understood that the present invention is not limited to the specific embodiments disclosed, but is intended to cover modifications within the spirit and scope of the present invention as defined in this specification.

[0112] Material

[0113]

[0114]

[0115] Cell lines

[0116] FreeStyle 293F cell line (ThermoFisher Scientific, catalog number R79007) Vector construction body

[0117] pcDNA3.1-α6 / 3 (α6 / 3 chimera, α6: 1-338; 465-505, α3: 339-464)

[0118] pCMV6-XL5-β2

[0119] pcDNA3.1-β3

[0120] pcDNA3.1-BARP

[0121] pcDNA3.1-NACHO

[0122] pcDNA3.1-SULT2B1

[0123] pcDNA3.1-LAMP5

[0124] pcDNA3.1-CHAT

[0125] Culture medium

[0126] FreeStyle 293 Expression Medium

[0127] Transfection reagents

[0128] FectoPRO DNA transfection reagent

[0129] Inoculation medium

[0130] DMEM+L-glutamine+sodium pyruvate

[0131] 10% FBS

[0132] 1X Pen / Strep

[0133] Compound diluent / Ca5 buffer

[0134] Supplemented with 1 mM Mg 2+ and 2 mM Ca 2+ HEPES buffered saline solution (500ml) Calcium 5 (Ca5) dye (Molecular Devices)

[0135] Calcium dye diluted at 25X concentration in Hanks buffered saline. Dye diluted to 1X in HEPES assay buffer containing 2 mM CaCl2 and 1 mM MgCl2.

[0136] Methods and Process

[0137] Day 1 Cell Preparation

[0138] Prepare 1 × 10 cells by centrifuging and resuspending in fresh, pre-warmed culture medium. 6 Details

[0139] There is no need to readjust the cell density on the day of transfection.

[0140] Day 2 transfection

[0141] The following protocol uses a 100 mL transfection as an example. While shaking 90 mL of cells, prepare the following transfection mix in 10 mL of Freestyle 293 Expression Medium.

[0142] Vortex before adding 75 μl of FectoPRO (0.75 ul reagent / mL total medium) to an empty 50 ml tube. Reagent 5 seconds.

[0143] In a second 50 ml tube, dilute 50 μg DNA (0.5 μg total DNA / mL total medium; 1:1 for all plasmids) in Freestyle 293 Expression Medium to a final volume of 10 ml. Vortex gently.

[0144] Transfer all diluted DNA to pure The solution was immediately homogenized and incubated at room temperature for 10 minutes.

[0145] ·10ml Transfer the DNA / transfection mixture to the cells and homogenize the culture.

[0146] Day 3: Plating cells

[0147] Spin cells at 300 x G for 5 min, aspirate supernatant, and resuspend in 10 ml plating medium.

[0148] Seed 25,000 cells / well (5×10 5 cells / mL).

[0149] - Incubate the plates at 30°C and 5% CO2 in a humidified atmosphere for 24 hours.

[0150] Day 4 FLPR assay

[0151] - Wash the plate using a plate washer (4 washes x 100 μL / wash) with compound dilution buffer, leaving 25 μL in each well.

[0152] • Add 25 μl of 2X Ca5 dye to each well.

[0153] Incubate at room temperature for 1 hour.

[0154] - Wash the plate with compound dilution buffer using a plate washer (4 washes x 100 μL / wash), leaving 25 μL in each well.

[0155] Antagonists

[0156] Transfer plates to FLIPR for compound additions. 1st Addition Plate - 2x Antagonist (25 μL test compound). 2nd Addition Plate - 1x Antagonist, 3x Agonist (25 μL Nicotine EC80) EC80 Nicotine 236nM (25 μL; 3x = 708nM). Antagonist control wells are in columns 23 and 24. Positive control wells receive IC100 DHBe on first addition

[0157] (25 μL; 3x=30 μM), and the negative control received buffer (25 μL). The second addition to the control wells was IC100 DHBe (10 μM) and EC80 Nicotine 236 nM

[0158] (25 μL; 3x=708 nM).

[0159] Agonists

[0160] • Transfer plates to FLIPR for compound additions. Single addition plate for 2x agonist (25 μL). Control wells for agonist will be in columns 23 and 24. Positive control wells receive EC100 nicotine (25 μL; 2x = 2 μM). Negative control wells receive buffer + vehicle (25 μL).

[0161] Functional expression of α6β2β3 nAChR

[0162] Nucleic acids encoding human α6, β2, and β3 subunits of nAChR were co-transfected with specific combinations of cDNA (BARP+SULT2B1+LAMP5+NACHO or BARP+SULT2B1+LAMP5+NACHO+CHAT) into HEK293T cells and incubated overnight at 37°C and then at 30°C for 24-48 hours. The transfected cells were incubated with Ca5 dye at room temperature for one hour and then stained with E max Nicotine (10 μM) stimulation. Nicotine-induced Ca 2+ The signal diagram is shown in Figure 1A As shown, co-transfection with BARP, SULT2B1, LAMP5, NACHO, and CHAT (labeled "+CHAT") enhanced α6β2β3 nAChR function (ie, nicotine-induced calcium flux) compared to co-transfection with BARP, SULT2B1, LAMP5, and NACHO (labeled "-CHAT").

[0163] Functional expression of α6 / 3β2β3 nAChR

[0164] Nucleic acids encoding chimeric α6 / 3 subunits of nAChR and human β2 and β3 subunits were co-transfected with specific combinations of cDNA (BARP+SULT2B1+LAMP5+NACHO or BARP+SULT2B1+LAMP5+NACHO+CHAT) into HEK293T cells and incubated overnight at 37°C. The transfected cells were incubated with Ca5 dye for one hour at room temperature and then stained with E max Nicotine (10 μM) stimulation. Nicotine-induced Ca 2+ The signal diagram is shown in Figure 1B As shown, co-transfection with BARP, SULT2B1, LAMP5, NACHO, and CHAT (labeled "+CHAT") enhanced α6 / 3β2β3 nAChR function (ie, nicotine-induced calcium flux) compared to co-transfection with BARP, SULT2B1, LAMP5, and NACHO (labeled "-CHAT").

[0165] Separately, transfected HEK293T cells were incubated at 30°C for 24-48 hours before incubation with Ca5 dye and stimulation with nicotine. Nicotine (10 μM)-induced Ca 2+ The signal diagram is shown in Figure 1CHere again, co-transfection with BARP, SULT2B1, LAMP5, NACHO, and CHAT (labeled "+CHAT") enhanced α6 / 3β2β3 nAChR function (i.e., nicotine-induced calcium flux) compared to co-transfection with BARP, SULT2B1, LAMP5, and NACHO (labeled "-CHAT"). In addition, transfected cells incubated at 30°C exhibited much higher nAChR function (i.e., nicotine-induced calcium flux) than those incubated at 37°C, which allows for more robust screening of modulators of α6-containing nAChRs.

[0166] Concentration-response curves of antagonists on nicotine-induced α6 / 3β2β3 nAChR activity

[0167] As described above, HEK293T cells transfected with nucleic acids encoding the α6 / 3, β2, and β3 subunits of nAChR and nucleic acids encoding BARP, SULT2B1, LAMP5, NACHO, and CHAT were incubated at 30°C for 24-48 hours. The transfected cells were then incubated with Ca5 dye for one hour at room temperature and subsequently stimulated using a two-addition protocol (1st addition: 3 min stimulation with different concentrations of antagonists (i.e., DHbE, MLA, mecamylamine, or α-conotoxin MII); 2nd addition: 3.5 min stimulation with nicotine (EC80, 236 nm). FLIPR was then used to TETRA The imager measured nicotine-induced calcium flux, and the resulting FLIPR signals were averaged and plotted ( Figure 2A-2D ). As shown, each of the antagonists tested reduced nicotine-evoked calcium flux in a dose-dependent manner.

Claims

1. An isolated recombinant cell comprising: a) a heterologous nucleic acid encoding the α6 subunit of nAChR; b) a heterologous nucleic acid encoding a BARP; c) a heterologous nucleic acid encoding SULT2B1; d) a heterologous nucleic acid encoding LAMP5; e) a heterologous nucleic acid encoding CHAT; and f) a heterologous nucleic acid encoding NACHO.

2. The isolated recombinant cell according to claim 1, further comprising: g) a heterologous nucleic acid encoding the β2 subunit of nAChR; and h) a heterologous nucleic acid encoding the β3 subunit of nAChR, in, The α6 subunit, the β2 subunit and the β3 subunit of nAChR form α6β2β3 nAChR.

3. The isolated recombinant cell according to claim 1 or 2, wherein the α6 subunit of nAChR is an α6 / 3 chimera, wherein all or part of the sequence of the second intracellular loop (ICL) of the α6 subunit is replaced by the corresponding sequence of the second ICL of the α3 subunit of nAChR, and wherein the α6 / 3 chimera of nAChR forms a chimeric α6 / 3β2β3nAChR with the β2 subunit and the β3 subunit.

4. The isolated recombinant cell according to any one of claims 1 to 3, wherein the recombinant cell is a mammalian cell.

5. The isolated recombinant cell of claim 4, wherein the mammalian cell is selected from the group consisting of human embryonic kidney 293T (HEK293T) cells, HEK293F cells, HeLa cells, Chinese hamster ovary (CHO) cells, NIH3T3 cells, MCF-7 cells, Hep G2 cells, baby hamster kidney (BHK) cells, and Cos7 cells.

6. The isolated recombinant cell of any one of claims 1 to 5, wherein the α6 subunit of nAChR comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

1.

7. The isolated recombinant cell of any one of claims 2 to 6, wherein the β2 subunit of nAChR comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

6.

8. The isolated recombinant cell of any one of claims 2 to 7, wherein the β3 subunit of nAChR comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

7.

9. The isolated recombinant cell according to any one of claims 3 to 8, wherein the second ICL of the α6 subunit comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:2, and the second ICL of the α3 subunit comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

4.

10. The isolated recombinant cell of any one of claims 3 to 9, wherein the α6 / 3 chimera comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

5.

11. The isolated recombinant cell of any one of claims 1 to 10, wherein the BARP comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

8. 12 . The isolated recombinant cell of claim 1 , wherein the SULT2B1 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

9.

13. The isolated recombinant cell of any one of claims 1 to 12, wherein the LAMP5 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

10.

14. The isolated recombinant cell of any one of claims 1 to 13, wherein the CHAT comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

11.

15. The isolated recombinant cell of any one of claims 1 to 14, wherein the NACHO comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

12.

16. A method for identifying an agonist, antagonist or positive allosteric modulator of an α6-containing nAChR, the method comprising: a) contacting the isolated recombinant cell according to any one of claims 1 to 15 with a pharmaceutical agent; as well as b) determining the activity of the α6-containing nAChR of the isolated recombinant cell, wherein if the agent enhances the activity of the α6-containing nAChR, compared to the activity of the α6-containing nAChR when the isolated recombinant cell is not contacted with the agent, the agent is identified as an agonist or a positive allosteric modulator (PAM), and if the agent decreases the activity of the α6-containing nAChR, the agent is identified as an antagonist.

17. A method for identifying an agonist, antagonist or positive allosteric modulator of α6β2β3 nAChR, the method comprising: a) contacting the isolated recombinant cell according to any one of claims 2 to 15 with a pharmaceutical agent; as well as b) determining the activity of the α6β2β3nAChR of the isolated recombinant cell, wherein if the agent enhances the activity of the α6β2β3nAChR, compared to the activity of the α6β2β3nAChR when the isolated recombinant cell is not contacted with the agent, the agent is identified as an agonist or a positive allosteric modulator (PAM), and if the agent decreases the activity of the α6β2β3nAChR, the agent is identified as an antagonist.

18. The method of claim 17, wherein step b) comprises measuring calcium flux of the isolated recombinant cell, wherein the agent is identified as an agonist if the agent enhances the calcium flux compared to the calcium flux when the isolated recombinant cell is not contacted with the agent.

19. The method of claim 17, wherein step b) comprises measuring calcium flux and nicotine-induced calcium flux of the isolated recombinant cells, wherein the agent is identified as a PAM if the agent does not enhance calcium flux and enhances the nicotine-induced calcium flux as compared to the calcium flux and nicotine-induced calcium flux when the isolated recombinant cells are not contacted with the agent.

20. The method of claim 17, wherein step b) comprises measuring nicotine-induced calcium flux of the isolated recombinant cells, wherein the agent is identified as an antagonist if the agent reduces the nicotine-induced calcium flux as compared to the nicotine-induced calcium flux when the isolated recombinant cells are not contacted with the agent.

21. The method of any one of claims 16 to 20, wherein the isolated recombinant cells are incubated at about 25°C-35°C for about 20 hours-50 hours prior to contacting with the agent.

22. The method of any one of claims 16 to 21, wherein the agent is a small molecule or a peptide.

23. A kit comprising (i) the isolated recombinant cell according to any one of claims 1 to 15, and (ii) instructions for use.